| Cat.No. | Name | Information |
|---|---|---|
| M40870 | RVT-3101 | RVT-3101 is a potential first-in-class anti-tumor necrosis factor (TNF)-like ligand 1A (TL1A) monoclonal antibody for use in studies related to inflammatory bowel disease (IBD). |
| M40854 | Elranatamab | Elranatamab is a humanized IgG2ҡ bispecific T-cell inducing antibody that targets CD3 and B-cell maturation antigen (BCMA) on the surface of T-cells, resulting in activation of T-cells and the release of a variety of pro-inflammatory cytokines that lead to multiple myeloma cell lysis. It can be used in studies related to relapsed or refractory multiple myeloma (RRMM). |
| M40646 | CDX-1140 | CDX-1140 is an anti-CD40 human IgG2 monoclonal antibody that activates dendritic cells and B cells and drives NF-kB stimulation in CD40-expressing reporter cell lines. |
| M40611 | PF-04236921 | PF-04236921 is a fully human IgG2 monoclonal antibody targeting the interleukin IL-6 for studies related to Crohn's disease and rheumatoid arthritis. |
| M40609 | Eblasakimab | Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Rα1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD). |
| M40602 | Alacizumab | Alacizumab is a monoclonal antibody against VEGFR2 that can be used in cancer-related studies. |
| M40600 | Ebronucimab | Ebronucimab is a monoclonal antibody to PCSK9 that can be used in studies related to hypercholesterolemia. |
| M40598 | Serclutamab | Serclutamab is a monoclonal antibody to EGFR that can be used in studies related to solid tumors. |
| M40597 | Ametumumab | Ametumumab is a recombinant fully human anti-EGFR monoclonal antibody that can be used in studies related to colorectal cancer. |
| M40596 | Pimurutamab | Pimurutamab is a monoclonal antibody to EGFR that can be used in tumor-related studies. |
| M40595 | Pidilizumab | Pidilizumab is a monoclonal antibody to PD-1 that can be used in studies related to diffuse large B-cell lymphoma (DLBCL). |
| M40594 | Genolimzumab | Genolimzumab is a PD-1 monoclonal antibody that can be used in studies related to peripheral T-cell lymphoma (PTCL). |
| M40593 | Brolucizumab | Brolucizumab is a humanized single-chain anti-VEGF-A variable antibody fragment (scFv) that can be used in studies related to macular degeneration. |
| M40592 | Certolizumab | Certolizumab is a recombinant, polyethylene glycolated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumor necrosis factor (TNF)-alpha, and may be used in psoriasis-related studies. |
| M40552 | Osemitamab | Osemitamab (TST001) is a recombinant humanized, IgG1 antibody targeting CLDN18.2, consisting of the human mouse monoclonal TST001 γ-1 chain polymerized via disulfide bonding with the human mouse monoclonal TST001 κ-chain dimer (ACI). It can be used in studies related to bile duct tumors. |
| M31300 | Faricimab | Faricimab is a bispecific antibody targeting Ang II and VEGF-A for studies related to eye disease and cardiovascular disease. |
| M31299 | Zebituzumab | Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma. |
| M31121 | Dinutuximab | Dinutuximab is an anti-disialytic ganglioside antigen (GD2) antibody with anticancer activity for studies related to pediatric neuroblastoma. |
| M25443 | Necitumumab | Necitumumab is a second-generation fully humanized immunoglobulin G1 (IgG1), epidermal growth factor (EGFR) receptor monoclonal antibody that specifically blocks the ligand binding site of EGFR. |
| M25387 | Daclizumab | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
